Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Receivables (2018 - 2026)

10x Genomics' Receivables history spans 8 years, with the latest figure at $82.5 million for Q4 2025.

  • On a quarterly basis, Receivables fell 6.75% to $82.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $82.5 million, a 6.75% decrease, with the full-year FY2025 number at $82.5 million, down 6.75% from a year prior.
  • Receivables hit $82.5 million in Q4 2025 for 10x Genomics, down from $96.6 million in the prior quarter.
  • Over the last five years, Receivables for TXG hit a ceiling of $119.1 million in Q2 2025 and a floor of $52.5 million in Q1 2025.
  • Historically, Receivables has averaged $85.5 million across 5 years, with a median of $84.4 million in 2021.
  • Biggest five-year swings in Receivables: skyrocketed 162.61% in 2021 and later plummeted 42.45% in 2025.
  • Tracing TXG's Receivables over 5 years: stood at $85.3 million in 2021, then rose by 22.24% to $104.2 million in 2022, then rose by 10.19% to $114.8 million in 2023, then dropped by 22.96% to $88.5 million in 2024, then fell by 6.75% to $82.5 million in 2025.
  • Business Quant data shows Receivables for TXG at $82.5 million in Q4 2025, $96.6 million in Q3 2025, and $119.1 million in Q2 2025.